Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mavorixafor trial in WHIM syndrome with open-label extension
2024-518461-10-00Phase 3Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of mavorixafor in WHIM syndrome (WHIM) (3 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Time above threshold absolute neutrophil count and Safety and tolerability. Started Nov 2024; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on 2024-518461-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518461-10-00.